Last updated: 2026-09-25 10:10:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Immunic, Inc. (IMUX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $9.37, with a market capitalization of $127.85M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.06 to $17.43. This page covers its latest market performance, valuation, price trends and company information.
$127.85M | |
$9.37 | |
$289.90 | |
$5.06 | |
$9.32 | |
1.20K | |
235.71K | |
-- | |
$17.43 | |
$5.06 | |
-- | |
-- |
Immunic, Inc. (IMUX) is trading at $9.37 in pre-market trading as of 2026-09-25 08:10:00, up 0.53% ($0.05) from the previous close of $9.32
Pre-market trading shows how investors are pricing IMUX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Immunic, Inc. (IMUX) moved from $10.12 to $9.37, representing a decline of 7.42% ($0.75).
The stock traded between $9.09 and $11.28 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 460.37 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 34.8%
IMUX is currently trading at $9.37, placing it 34.8% of the way from its 52-week low of $5.06 to its 52-week high of $17.43. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 95 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Immunic, Inc. (IMUX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.